Qualyst Transporter Solutions, LLC Announces New Alliance with GenoMembrane
The first integrated hepatocyte system to address the role of transporters and metabolism - now available in Japan
RESEARCH TRIANGLE PARK, N.C., Jan. 21, 2013 /PRNewswire-iReach/ -- Qualyst Transporter Solutions, LLC, has recently announced an alliance with GenoMembrane, Kanagawa, Japan to make available its B-CLEAR® Technology to customers in Japan. The initial offering will focus on supplying B-CLEAR® kits of rat and human hepatocytes, both plated with Transporter Certified™ hepatocytes. In addition, contract services projects can be facilitated through GenoMembrane. The alliance will facilitate access to B-CLEAR® technology in Japan, which can be used to predict the biliary excretion of drugs, evaluate clinically relevant drug interactions, determine the cholestatic potential of drugs, and estimate their intracellular concentration.
"B-CLEAR® human kits for Japan use cryopreserved human hepatocytes that have been certified for transporter function (uptake and efflux), providing the customer with clinically relevant data, and a high level of reproducibility from experiment to experiment." said Dr. Christopher Black , CEO for Qualyst Transporter Solutions.
Qualyst Transporter Solutions only uses Transporter Certified™ hepatocytes in its kits and services to examine the potential for in vivo relevant transporter-based drug interactions. The key to obtaining in vivo-relevant answers is to use a fully integrated, functioning cell system that has been certified for transporter function. "We certify our hepatocytes to ensure a fully functioning complement of uptake and efflux transporters, which guarantees that the results are in vivo-relevant," said Dr. Kenneth Brouwer , CSO for Qualyst Transporter Solutions.
"We are excited that we can now offer B-CLEAR® kits with both rat and human hepatocytes to our Japanese customers, as well as an opportunity to offer other relevant research services conducted by Qualyst Transporter Solutions," said Mr. Satoshi Senda , CEO for GenoMembrane.
About Qualyst Transporter Solutions, LLC
In addition to it's patented B-CLEAR® technology, Qualyst Transporter Solutions commercializes novel and proprietary drug transport and hepatobiliary disposition products for drug discovery and development. Qualyst Transporter Solutions products provide answers to transporter questions that arise in drug discovery and development. For additional information, please refer to the company's web site at www.qualyst.com or call (919) 313-6500. B-CLEAR® technology is covered by US (# 6780580), EU (#1163517) and JP (#4451570) patents issued and pending.
GenoMembrane Co., Ltd. provides transporter-related products and services that are critical in the development and design of novel drugs for clinical applications. GenoMembrane also provides research tools and collaborates for the pharmacological evaluation of drug candidates to minimize costs, help improve the success rate of candidate drugs, and speed up new drug development. For additional information, please refer to the company's web site at http://www.genomembrane.com/.
US: Qualyst Transporter Solutions, Christopher Black , Ph.D. Chief Executive Officer, (919) 313-6511, email@example.com
Japan: GenoMembrane, Satoshi Senda , Chief Executive Officer, +81(45)508-2326, firstname.lastname@example.org
SOURCE Qualyst Transporter Solutions, LLC
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.